Drug review: Carfilzomib
Carfilzomib is a second generation proteasome inhibitor approved for use in relapsed/ refractory multiple myeloma. The mechanism of action, usage, toxicity and key trials involving this agent are briefly reviewed here.
Сохранить в:
| Главный автор: | |
|---|---|
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
Thieme Medical and Scientific Publishers Pvt. Ltd.
2019-01-01
|
| Серии: | Indian Journal of Medical and Paediatric Oncology |
| Предметы: | |
| Online-ссылка: | http://www.ijmpo.org/article.asp?issn=0971-5851;year=2019;volume=40;issue=1;spage=130;epage=131;aulast=Ganesan |
| Метки: |
Нет меток, Требуется 1-ая метка записи!
|